Report cover image

Biomarkers Market by Type (Efficacy, Pharmacodynamics, Predictive), Product & Service (Consumables, Services, Software), Disease, Application - Global Forecast 2023-2030

Publisher 360iResearch
Published Oct 05, 2023
Length 195 Pages
SKU # IRE18313228

Description

Biomarkers Market by Type (Efficacy, Pharmacodynamics, Predictive), Product & Service (Consumables, Services, Software), Disease, Application - Global Forecast 2023-2030


The Biomarkers Market is projected to reach USD 153.67 billion by 2030 from USD 53.45 billion in 2022, at a CAGR of 14.10% during the forecast period.

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Biomarkers Market.
  • Based on Type, market is studied across Efficacy, Pharmacodynamics, Predictive, Prognostic, Safety, Surrogate, and Validation. The Efficacy commanded largest market share of 23.65% in 2022, followed by Validation.
  • Based on Product & Service, market is studied across Consumables, Services, and Software. The Consumables commanded largest market share of 50.87% in 2022, followed by Services.
  • Based on Disease, market is studied across Cancer, Cardiovascular Diseases, Immunological Diseases, Infectious Diseases, and Neurological Diseases. The Cancer commanded largest market share of 51.17% in 2022, followed by Neurological Diseases.
  • Based on Application, market is studied across Diagnostic, Disease Risk Assessment, Drug Discovery & Development, and Personalized Medicine. The Diagnostic commanded largest market share of 39.73% in 2022, followed by Drug Discovery & Development.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 39.50% in 2022, followed by Europe, Middle East & Africa.
Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Biomarkers Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Biomarkers Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alto Neuroscience,Inc., APIS Assay Technologies Limited, Augurex Life Sciences Corp, Bio-Rad Laboratories, Inc., BioAgilytix, Biocrates Life Sciences AG, Biofourmis Inc., Biognosys AG, BIOINFRA Life Science Inc., BioStarks, BioVision Inc., Charles River Laboratories, Inc., Clarigent Corporation, EKF Diagnostics Holdings PLC, Elo Health, Inc., F. Hoffmann-La Roche, Ltd., Merck KgaA, Nightingale Health Plc, Owkin Inc., Owlstone Medical Limited, PerkinElmer, Inc., Personalis, Inc., Proteomedix AG, QIAGEN GmbH, Renalytix PLC, Siemens Healthcare GmbH, Sino Biological Inc., Thermo Fisher Scientific, Inc., and VivoSense, Inc..

The report offers valuable insights on the following aspects:
  1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
  2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
  3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
  4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
  5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
  1. What is the market size and forecast for the Biomarkers Market?
  2. Which products, segments, applications, and areas hold the highest investment potential in the Biomarkers Market?
  3. What is the competitive strategic window for identifying opportunities in the Biomarkers Market?
  4. What are the latest technology trends and regulatory frameworks in the Biomarkers Market?
  5. What is the market share of the leading vendors in the Biomarkers Market?
  6. Which modes and strategic moves are suitable for entering the Biomarkers Market?


Note: PDF & Excel + Online Access - 1 Year

Table of Contents

195 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Biomarkers Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing usage of biomarkers testing owing to monitor the treatment of chronic disease
5.1.1.2. Increasing biomarkers diagnostic application for personalized medicine
5.1.1.3. Rising research and development activities in biotechnology and pharmaceutical sector
5.1.2. Restraints
5.1.2.1. High cost associated with production and lengthy time process for biomarkers development
5.1.3. Opportunities
5.1.3.1. Recent advancements in the development of prognostic and diagnostic
biomarkers for cancer treatments
5.1.3.2. Integration of advanced technologies to develop biomarkers that provide high accuracy
5.1.4. Challenges
5.1.4.1. Issues associated with collection and storage of samples in biomarkers
procedures
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Biomarkers Market, by Type
6.1. Introduction
6.2. Efficacy
6.3. Pharmacodynamics
6.4. Predictive
6.5. Prognostic
6.6. Safety
6.7. Surrogate
6.8. Validation
7. Biomarkers Market, by Product & Service
7.1. Introduction
7.2. Consumables
7.3. Services
7.4. Software
8. Biomarkers Market, by Disease
8.1. Introduction
8.2. Cancer
8.3. Cardiovascular Diseases
8.4. Immunological Diseases
8.5. Infectious Diseases
8.6. Neurological Diseases
9. Biomarkers Market, by Application
9.1. Introduction
9.2. Diagnostic
9.3. Disease Risk Assessment
9.4. Drug Discovery & Development
9.5. Personalized Medicine
10. Americas Biomarkers Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Biomarkers Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Biomarkers Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
13.3.1. Merger & Acquisition
13.3.1.1. Theralink Acquires Immunotherapy Biomarker Patent From Vanderbilt University
13.3.1.2. Mainz Biomed Acquires Entire Intellectual Property Portfolio For Its Colorectal Cancer Diagnostic Test Program
13.3.2. Agreement, Collaboration, & Partnership
13.3.2.1. ObvioHealth Signs R&D Partnership with A*STAR to Identify and Develop Novel Digital Biomarkers
13.3.2.2. PrecisionLife Completes Agreement with King’s College London to Enable New Precision Neuroscience Treatments in MND/ALS
13.3.2.3. AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. Announce Strategic Partnership to Advance Biomarker Development for Alzheimer’s Disease and Neurodegeneration
13.3.2.4. Vocal Biomarker Agreement Set To Benefit Patients With COPD in India
13.3.3. New Product Launch & Enhancement
13.3.3.1. Akoya Biosciences Launches PhenoCode Signature Panels to Accelerate Development of Predictive Biomarkers for Cancer Immunotherapy
13.3.4. Investment & Funding
13.3.4.1. Genialis Raises USD 13 Million to Build Clinical Biomarkers that Predict Patient Response
13.3.5. Award, Recognition, & Expansion
13.3.5.1. Abbott Receives FDA Clearance For First Commercially Available Lab-Based Blood Test To Help Evaluate Concussion
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Abbott Laboratories
14.1.2. Alto Neuroscience,Inc.
14.1.3. APIS Assay Technologies Limited
14.1.4. Augurex Life Sciences Corp
14.1.5. Bio-Rad Laboratories, Inc.
14.1.6. BioAgilytix
14.1.7. Biocrates Life Sciences AG
14.1.8. Biofourmis Inc.
14.1.9. Biognosys AG
14.1.10. BIOINFRA Life Science Inc.
14.1.11. BioStarks
14.1.12. BioVision Inc.
14.1.13. Charles River Laboratories, Inc.
14.1.14. Clarigent Corporation
14.1.15. EKF Diagnostics Holdings PLC
14.1.16. Elo Health, Inc.
14.1.17. F. Hoffmann-La Roche, Ltd.
14.1.18. Merck KgaA
14.1.19. Nightingale Health Plc
14.1.20. Owkin Inc.
14.1.21. Owlstone Medical Limited
14.1.22. PerkinElmer, Inc.
14.1.23. Personalis, Inc.
14.1.24. Proteomedix AG
14.1.25. QIAGEN GmbH
14.1.26. Renalytix PLC
14.1.27. Siemens Healthcare GmbH
14.1.28. Sino Biological Inc.
14.1.29. Thermo Fisher Scientific, Inc.
14.1.30. VivoSense, Inc.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us